113 related articles for article (PubMed ID: 8669887)
1. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.
Iino Y; Yokoe T; Maemura M; Horiguchi J; Takei H; Ohwada S; Morishita Y
Anticancer Res; 1995; 15(6B):2907-11. PubMed ID: 8669887
[TBL] [Abstract][Full Text] [Related]
2. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
[TBL] [Abstract][Full Text] [Related]
3. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y
Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177
[TBL] [Abstract][Full Text] [Related]
4. [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2241-9. PubMed ID: 2500070
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of subcutaneous mastectomy with radical mastectomy.
Horiguchi J; Iino JHY ; Takei H; Koibuchi Y; Iijima K; Ikeda F; Ochiai R; Uchida K; Yoshida M; Yokoe T; Morishita Y
Anticancer Res; 2001; 21(4B):2963-7. PubMed ID: 11712794
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Nakazato H; Koike A; Saji S; Ogawa N; Sakamoto J
Lancet; 1994 May; 343(8906):1122-6. PubMed ID: 7910230
[TBL] [Abstract][Full Text] [Related]
7. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer].
Nakazato H; Koike A; Ichihashi H; Saji S; Danno M; Ogawa N
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2563-76. PubMed ID: 2505682
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Dis Colon Rectum; 1992 Feb; 35(2):123-30. PubMed ID: 1735313
[TBL] [Abstract][Full Text] [Related]
9. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
[TBL] [Abstract][Full Text] [Related]
10. [[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group])].
Imaizumi M; Kondo T; Kamei H; Ichihashi H
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2397-403. PubMed ID: 2124433
[TBL] [Abstract][Full Text] [Related]
11. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer.
Tanaka H; Muguruma K; Ohira M; Kubo N; Yamashita Y; Maeda K; Sawada T; Hirakawa K
Anticancer Res; 2012 Aug; 32(8):3427-33. PubMed ID: 22843926
[TBL] [Abstract][Full Text] [Related]
12. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer.
Tsujitani S; Kakeji Y; Orita H; Watanabe A; Kohnoe S; Baba H; Anai H; Maehara Y; Sugimachi K
Anticancer Res; 1992; 12(3):645-8. PubMed ID: 1622120
[TBL] [Abstract][Full Text] [Related]
13. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
[TBL] [Abstract][Full Text] [Related]
15. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
Takahashi Y; Mai M; Nakazato H
Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
17. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Cameron DA; Gregory WM; Bowman A; Anderson ED; Levack P; Forouhi P; Leonard RC
Br J Cancer; 2000 Jul; 83(1):98-103. PubMed ID: 10883676
[TBL] [Abstract][Full Text] [Related]
18. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
